toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author (up) Mormont, M.-C.; Levi, F. url  doi
openurl 
  Title Cancer chronotherapy: principles, applications, and perspectives Type Journal Article
  Year 2003 Publication Cancer Abbreviated Journal Cancer  
  Volume 97 Issue 1 Pages 155-169  
  Keywords Human Health; Animals; Antineoplastic Combined Chemotherapy Protocols/*administration & dosage; Chronobiology Phenomena; *Chronotherapy; Colorectal Neoplasms/*drug therapy; Drug Tolerance; Humans; Models, Biological; Prognosis; Quality of Life  
  Abstract BACKGROUND: Cell physiology is regulated along the 24-hour timescale by a circadian clock, which is comprised of interconnected molecular loops involving at least nine genes. The cellular clocks are coordinated by the suprachiasmatic nucleus, a hypothalamic pacemaker that also helps the organism adjust to environmental cycles. The rest-activity rhythm is a reliable marker of the circadian system function in both rodents and humans. This circadian organization is responsible for predictable changes in the tolerability and efficacy of anticancer agents, and possibly also may be involved in tumor promotion or growth. METHODS: Expected least toxic times of chemotherapy were extrapolated from experimental models to human subjects with reference to the rest-activity cycle. The clinical relevance of the chronotherapy principle (i.e., treatment administration as a function of rhythms) has been investigated previously in randomized multicenter trials. RESULTS: In the current study, chronotherapeutic schedules were used to safely document activity of the combination of oxaliplatin, 5-fluorouracil, and leucovorin against metastatic colorectal carcinoma and to establish new medicosurgical management for this disease, and were reported to result in unprecedented long-term survival. CONCLUSIONS: Chronotherapy concepts appear to offer further potential to improve current cancer treatment options as well as to optimize the development of new anticancer or supportive agents.  
  Address EPI 0118 INSERM Chronotherapeutique des cancers and Service de Cancerologie, Hopital Paul Brousse (I.C.I.G), 94800 Villejuif Cedex, France  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 0008-543X ISBN Medium  
  Area Expedition Conference  
  Notes PMID:12491517 Approved no  
  Call Number LoNNe @ kagoburian @ Serial 785  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: